Sanofi: Goldman Sachs upgrades to buy
(CercleFinance.com) - An analyst at Goldman Sachs Equity Research today says that he has upgraded his recommendation on the Sanofi share, advising investors to buy it, against a previously neutral stance.
"We see European Pharma's growth outlook as largely unimpacted in the context of recent macro headwinds," Goldman Sachs explains.
The broker has also set a corresponding target price of 104 euros (29% upside).
Copyright (c) 2020 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.
"We see European Pharma's growth outlook as largely unimpacted in the context of recent macro headwinds," Goldman Sachs explains.
The broker has also set a corresponding target price of 104 euros (29% upside).
Copyright (c) 2020 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.